Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II first-line panitumumab plus dose-dense DCF/5-FU chemotherapy for advanced gastric or gastro-esophageal junction cancer
2009-016962-10Phase 2Completed
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of panitumumab in gastric cancer (GC) and esophagogastric junction cancer, sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Overall response rate. Started Jan 2010; status: completed.
02
Drugs
panitumumab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2009-016962-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016962-10.